Skip to main content
Top
Published in: Endocrine Pathology 1/2020

01-03-2020 | Pituitary Adenoma

A Novel Expression Profile of Cell Cycle and DNA Repair Proteins in Nonfunctioning Pituitary Adenomas

Authors: Derya Metin-Armagan, Nil Comunoglu, Gulay Bulut, Pinar Kadioglu, Hiraku Kameda, Nurperi Gazioglu, Necmettin Tanriover, Melek Ozturk

Published in: Endocrine Pathology | Issue 1/2020

Login to get access

Abstract

The molecular mechanisms underlying the formation of nonfunctioning pituitary adenomas (NFAs) are largely unknown. In this study, we aimed to understand the relationship between NFAs and functional pituitary adenomas and the possible role of proteins involved in cell cycle, senescence, and DNA damage control mechanisms in the etiology of NFA. We analyzed pATM-S1981, pRb-S608, Rb, pE2F1-S364, p16, E2F1, p73, cyclin D1, and CHEK2 protein expression (in a group of 20 patients with acromegaly, 18 patients with Cushing’s disease (CD), and 29 NFA patients) by immunohistochemistry and their relevant mRNA expression by qRT-PCR (in a group of 7 patients with acromegaly, 7 patients with CD, and 7 NFA patients). The clinical and histopathological results on the patients were statistically evaluated. pE2F1-S364 protein expression in the CD group was significantly lower than that in the NFA and acromegaly groups (p = 0.025, p = 0.034, respectively). However, the expression of the p16 protein was lower than in the NFA group than in the CD and acromegaly groups (p = 0.030, p = 0.033, respectively), and E2F1 protein expression was significantly higher in the NFA group than in the CD group (p = 0.025). p73 protein expression in patients with acromegaly was significantly higher (p = 0.031) than that in the CD group. CHEK2 mRNA expression in the CD group was significantly higher than that in the acromegaly group (p = 0.012). The selective and tumor-specific associations between E2F1, pE2F1-S364, CHEK2, and p73 mRNA and protein levels indicate their involvement in pituitary adenoma formation in NFA, CD, and acromegaly patients.
Literature
1.
go back to reference Melmed S (2011) Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7(5): p. 257-266.CrossRef Melmed S (2011) Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7(5): p. 257-266.CrossRef
2.
go back to reference Kovacs K, E Horvath, and S Vidal (2001) Classification of pituitary adenomas. J Neurooncol 54(2): p. 121-127.CrossRef Kovacs K, E Horvath, and S Vidal (2001) Classification of pituitary adenomas. J Neurooncol 54(2): p. 121-127.CrossRef
3.
go back to reference Melmed S (2003) Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112(11): p. 1603-1618.CrossRef Melmed S (2003) Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112(11): p. 1603-1618.CrossRef
4.
go back to reference Young WF Jr, Scheithauer BW, Kovacs KT et al (1996) Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clin Proc 71(7): p. 649-656.CrossRef Young WF Jr, Scheithauer BW, Kovacs KT et al (1996) Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clin Proc 71(7): p. 649-656.CrossRef
5.
go back to reference Moreno CS, Evans CO, Zhan X, Okor M, Desiderio DM, Oyesiku NM (2005) Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res 65(22): p. 10214-22.CrossRef Moreno CS, Evans CO, Zhan X, Okor M, Desiderio DM, Oyesiku NM (2005) Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res 65(22): p. 10214-22.CrossRef
6.
go back to reference Zhan X, et al (2014) Heterogeneity analysis of the proteomes in clinically nonfunctional pituitary adenomas. BMC Med Genomics 7: p. 69.CrossRef Zhan X, et al (2014) Heterogeneity analysis of the proteomes in clinically nonfunctional pituitary adenomas. BMC Med Genomics 7: p. 69.CrossRef
7.
go back to reference Schmitt CA et al (2002) A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109(3): p. 335-346.CrossRef Schmitt CA et al (2002) A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109(3): p. 335-346.CrossRef
8.
go back to reference Lee EH, Kim KH, Kwon JH, Kim HD, Kim YZ (2014) Results of immunohistochemical staining of cell-cycle regulators: the prediction of recurrence of functioning pituitary adenoma. World Neurosurg 81(3-4): p. 563-575.CrossRef Lee EH, Kim KH, Kwon JH, Kim HD, Kim YZ (2014) Results of immunohistochemical staining of cell-cycle regulators: the prediction of recurrence of functioning pituitary adenoma. World Neurosurg 81(3-4): p. 563-575.CrossRef
9.
go back to reference Chesnokova V et al (2011) Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One 6(3): p. e17924.CrossRef Chesnokova V et al (2011) Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One 6(3): p. e17924.CrossRef
10.
go back to reference Carnevale J et al (2012) DNA damage signals through differentially modified E2F1 molecules to induce apoptosis. Mol Cell Biol 32(5): p. 900-912.CrossRef Carnevale J et al (2012) DNA damage signals through differentially modified E2F1 molecules to induce apoptosis. Mol Cell Biol 32(5): p. 900-912.CrossRef
11.
go back to reference Araki T, Liu NA, Tone Y, Cuevas-Ramos D, Heltsley R, Tone M, Melmed S (2016) E2F1-mediated human POMC expression in ectopic Cushing’s syndrome. Endocr Relat Cancer 23(11): p. 857-870.CrossRef Araki T, Liu NA, Tone Y, Cuevas-Ramos D, Heltsley R, Tone M, Melmed S (2016) E2F1-mediated human POMC expression in ectopic Cushing’s syndrome. Endocr Relat Cancer 23(11): p. 857-870.CrossRef
12.
go back to reference Zhou C, Wawrowsky K, Bannykh S, Gutman S, Melmed S (2009) E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. Mol Endocrinol 23(12): p. 2000-12.CrossRef Zhou C, Wawrowsky K, Bannykh S, Gutman S, Melmed S (2009) E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. Mol Endocrinol 23(12): p. 2000-12.CrossRef
13.
go back to reference Fedele M et al (2006) E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression. Cell Div 1: p. 17.CrossRef Fedele M et al (2006) E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression. Cell Div 1: p. 17.CrossRef
14.
go back to reference Ozkaya HM, Comunoglu N, Sayitoglu M, Keskin FE, Firtina S, Khodzhaev K, Apaydin T, Gazioglu N, Tanriover N, Oz B, Kadioglu P (2018) Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues. Pituitary 21(4): p. 335-346.CrossRef Ozkaya HM, Comunoglu N, Sayitoglu M, Keskin FE, Firtina S, Khodzhaev K, Apaydin T, Gazioglu N, Tanriover N, Oz B, Kadioglu P (2018) Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues. Pituitary 21(4): p. 335-346.CrossRef
15.
go back to reference Kaya-Dagistanli F, Tanriverdi G, Altinok A, Ozyazgan S, Ozturk M (2013) The effects of alpha lipoic acid on liver cells damages and apoptosis induced by polyunsaturated fatty acids. Food Chem Toxicol 53: p. 84-93.CrossRef Kaya-Dagistanli F, Tanriverdi G, Altinok A, Ozyazgan S, Ozturk M (2013) The effects of alpha lipoic acid on liver cells damages and apoptosis induced by polyunsaturated fatty acids. Food Chem Toxicol 53: p. 84-93.CrossRef
16.
go back to reference Tani Y, Inoshita N, Sugiyama T, Kato M, Yamada S, Shichiri M, Hirata Y (2010) Upregulation of CDKN2A and suppression of cyclin D1 gene expressions in ACTH-secreting pituitary adenomas. Eur J Endocrinol 163(4): p. 523-529.CrossRef Tani Y, Inoshita N, Sugiyama T, Kato M, Yamada S, Shichiri M, Hirata Y (2010) Upregulation of CDKN2A and suppression of cyclin D1 gene expressions in ACTH-secreting pituitary adenomas. Eur J Endocrinol 163(4): p. 523-529.CrossRef
17.
go back to reference Attwooll C, E Lazzerini Denchi, and K Helin (2004) The E2F family: specific functions and overlapping interests. EMBO J 23(24): p. 4709-4716.CrossRef Attwooll C, E Lazzerini Denchi, and K Helin (2004) The E2F family: specific functions and overlapping interests. EMBO J 23(24): p. 4709-4716.CrossRef
18.
go back to reference Simpson D.J et al (2000) Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 60(5): p. 1211-1216.PubMed Simpson D.J et al (2000) Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 60(5): p. 1211-1216.PubMed
19.
go back to reference Indovina P, Pentimalli F, Casini N, Vocca I, Giordano A (2015) RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy. Oncotarget 6(20): p. 17873-17890.CrossRef Indovina P, Pentimalli F, Casini N, Vocca I, Giordano A (2015) RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy. Oncotarget 6(20): p. 17873-17890.CrossRef
20.
go back to reference van den Heuvel S. and N.J Dyson (2008) Conserved functions of the pRB and E2F families. Nat Rev Mol Cell Biol 9(9): p. 713-724.CrossRef van den Heuvel S. and N.J Dyson (2008) Conserved functions of the pRB and E2F families. Nat Rev Mol Cell Biol 9(9): p. 713-724.CrossRef
21.
go back to reference Geoffrey M Cooper, REH (2015) The Cell Cycle in The Cell: A Molecular Approach Sİnauer Associates.: Washington, D.C Geoffrey M Cooper, REH (2015) The Cell Cycle in The Cell: A Molecular Approach Sİnauer Associates.: Washington, D.C
22.
go back to reference Bae WK, Hong CS, Park MR, Sun EG, Lee JH, Kang K, Ryu KH, Shim HJ, Hwang JE, Cho SH, Chung IJ (2018) TAp73 inhibits cell invasion and migration by directly activating KAI1 expression in colorectal carcinoma. Cancer Lett 415: p. 106-116.CrossRef Bae WK, Hong CS, Park MR, Sun EG, Lee JH, Kang K, Ryu KH, Shim HJ, Hwang JE, Cho SH, Chung IJ (2018) TAp73 inhibits cell invasion and migration by directly activating KAI1 expression in colorectal carcinoma. Cancer Lett 415: p. 106-116.CrossRef
23.
go back to reference Roussel-Gervais A et al (2016) The Cables1 Gene in Glucocorticoid Regulation of Pituitary Corticotrope Growth and Cushing Disease. J Clin Endocrinol Metab 101(2): p. 513-522.CrossRef Roussel-Gervais A et al (2016) The Cables1 Gene in Glucocorticoid Regulation of Pituitary Corticotrope Growth and Cushing Disease. J Clin Endocrinol Metab 101(2): p. 513-522.CrossRef
24.
go back to reference Bird AD, Tan KH, Olsson PF, Zieba M, Flecknoe SJ, Liddicoat DR, Mollard R, Hooper SB, Cole TJ (2007) Identification of glucocorticoid-regulated genes that control cell proliferation during murine respiratory development. J Physiol 585(Pt 1): p. 187-201.CrossRef Bird AD, Tan KH, Olsson PF, Zieba M, Flecknoe SJ, Liddicoat DR, Mollard R, Hooper SB, Cole TJ (2007) Identification of glucocorticoid-regulated genes that control cell proliferation during murine respiratory development. J Physiol 585(Pt 1): p. 187-201.CrossRef
Metadata
Title
A Novel Expression Profile of Cell Cycle and DNA Repair Proteins in Nonfunctioning Pituitary Adenomas
Authors
Derya Metin-Armagan
Nil Comunoglu
Gulay Bulut
Pinar Kadioglu
Hiraku Kameda
Nurperi Gazioglu
Necmettin Tanriover
Melek Ozturk
Publication date
01-03-2020
Publisher
Springer US
Published in
Endocrine Pathology / Issue 1/2020
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-019-09598-x

Other articles of this Issue 1/2020

Endocrine Pathology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.